Q4 2025 gMG Market Driven by Clinical Progress and Regulatory Milestones 

EMD Serono highlighted ongoing clinical activity for cemdisiran and enrollment efforts in gMG.

AstraZeneca shared updates from a key clinical program for Gefurulimab.

Novartis promoted a recent regulatory milestone for Rhapsido.

UCB promoted Rhapsido alongside communicated corporate updates and disease awareness efforts.

Amgen distributed HCP-focused materials tied to a recent approval for Uplizna.

Argenx outlined anticipated regulatory progress and upcoming data disclosures for Vyvgart.

UCB also reported positive EU regulatory development for Zilbrysq and introduced a new device format.